Even though endogenous ghrelin levels are increased in diseases such as cancer [58], renal failure [59], and cardiac failure [60], administration of ghrelin or ghrelin analogues to animal models and humans with these conditions results in improvements in lean body mass and appetite and a decrease in circulating inflammatory cytokines [11, 28, 29, 61–65]. The gene discussed is GHRL; the disease is kidney failure.